|
|
|
|
|
|
|
M Tue W Th F |
|
19 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Last year, Novo Nordisk rejigged its R&D activities with the aim of becoming faster and more agile. Elizabeth Cairns talks with the company's head of global research Jacob Sten Petersen about AI, RNAi and integrating bought-in assets. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Jacob Sten Petersen, Novo Nordisk head of global research |
|
|
|
by Elizabeth Cairns
|
Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganizeits R&D activities... | |
|
|
|
 |
|
Paul Bolno, Wave Life Sciences CEO |
|
|
|
by Lei Lei Wu
|
Wave Life Sciences reportedan updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised$110 million in a... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer... | |
|
|
|
|
|
|
by Reynald Castaneda
|
BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce... | |
|
|
|
|
|
